[go: up one dir, main page]

BR0311491A - Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero - Google Patents

Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero

Info

Publication number
BR0311491A
BR0311491A BR0311491-0A BR0311491A BR0311491A BR 0311491 A BR0311491 A BR 0311491A BR 0311491 A BR0311491 A BR 0311491A BR 0311491 A BR0311491 A BR 0311491A
Authority
BR
Brazil
Prior art keywords
compound
mammal
pharmaceutical composition
treat cancer
therapeutic method
Prior art date
Application number
BR0311491-0A
Other languages
English (en)
Inventor
Jerome P Horwitz
Thomas H Corbett
Eduardo Palomino
Lisa Polin
Stuart T Hazeldine
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Publication of BR0311491A publication Critical patent/BR0311491A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, MéTODO TERAPêUTICO PARA TRATAR CâNCER EM UM MAMìFERO". A invenção proporciona compostos da fórmula (I): em que A, X, Y, e Z são como definido no relatório descritivo. Os compostos constituem agentes anti-tumor efetivos. A invenção também proporciona composições farmacêuticas compreendendo um composto da fórmula acima ou um sal do mesmo, intermediários úteis para preparar um composto da fórmula acima, e métodos terapêuticos compreendendo administrar um composto da fórmula acima ou um sal do mesmo a um mamífero que disto necessita.
BR0311491-0A 2002-07-03 2003-07-03 Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero BR0311491A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39385802P 2002-07-03 2002-07-03
PCT/US2003/021062 WO2004005260A1 (en) 2002-07-03 2003-07-03 A-`7-halo-2-quino (xa-) linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents

Publications (1)

Publication Number Publication Date
BR0311491A true BR0311491A (pt) 2005-04-26

Family

ID=30115656

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311491-0A BR0311491A (pt) 2002-07-03 2003-07-03 Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero

Country Status (18)

Country Link
US (3) US7109341B2 (pt)
EP (1) EP1539699A1 (pt)
JP (1) JP2005532397A (pt)
CN (1) CN1688547A (pt)
AU (2) AU2003249722A1 (pt)
BR (1) BR0311491A (pt)
CA (1) CA2491612C (pt)
EA (1) EA009679B1 (pt)
GE (1) GEP20074058B (pt)
IL (1) IL164555A0 (pt)
MX (1) MXPA05000233A (pt)
NO (1) NO20050573L (pt)
NZ (1) NZ535887A (pt)
PL (1) PL373624A1 (pt)
SG (1) SG145570A1 (pt)
UA (1) UA79293C2 (pt)
WO (2) WO2004004651A2 (pt)
ZA (1) ZA200408191B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL367340A1 (en) * 2001-07-31 2005-02-21 Wayne State University Quinoline derivatives and use thereof as antitumor agents
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents
UA79480C2 (en) * 2002-08-24 2007-06-25 Zentaris Gmbh Disorazol containing drug for treating benign and malignant tumors
CN100427482C (zh) * 2005-08-01 2008-10-22 复旦大学 N,n-二甲胺酰基-2,3-二呋喃基-6-氨基喹噁啉,其制备方法与应用
US8183379B2 (en) * 2005-09-07 2012-05-22 Wayne State University Antitumor agents
US20070054938A1 (en) * 2005-09-07 2007-03-08 Horwitz Jerome P Antitumor agents
US7470788B2 (en) * 2005-09-07 2008-12-30 Wayne State University Antitumor agents
EP1897542A1 (en) * 2006-09-07 2008-03-12 Sanofi-Aventis Aqueous formulation comprising an antitumor agent
EP2146722A4 (en) * 2007-05-10 2011-08-03 Amr Technology Inc ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND THEIR USE FOR BLOCKING THE RECOVERY OF NOREPINEPHRIN, DOPAMINE AND SEROTONINE
EP2516396A1 (en) 2009-12-23 2012-10-31 Wayne State University Therapeutic compounds
CN103127112A (zh) * 2013-02-27 2013-06-05 江苏先声药物研究有限公司 一类喹啉酮衍生物在肿瘤治疗中的应用
CN105085480B (zh) * 2014-05-16 2017-12-29 湖南大学 2‑[4‑（喹喔啉‑2‑氧基）苯氧基]脂肪酰吡啶胺的医药用途
CN105085506B (zh) * 2014-05-16 2018-01-19 湖南大学 2‑[4‑(苯并噁唑‑2‑氧基)苯氧基]脂肪酰吡啶胺的医药用途
CN107827828B (zh) * 2017-11-21 2021-03-30 南京华漫新材料科技有限公司 含苯酰肼骨架的喹喔啉衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN110698418B (zh) * 2019-09-11 2022-07-01 广西师范大学 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用
TWI826034B (zh) * 2022-10-07 2023-12-11 宏碁股份有限公司 影像過曝改善方法及電子裝置

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54112628A (en) 1978-02-23 1979-09-03 Canon Inc Electromagnetic driving device
JPS6033389B2 (ja) * 1979-02-22 1985-08-02 日産化学工業株式会社 複素環エ−テル系フェノシキ脂肪酸誘導体、その製造法および該誘導体を含有する除草剤
US5364831A (en) * 1980-08-06 1994-11-15 Nissan Chemical Industries Ltd. Quinoxaline derivatives and herbicidal composition
US6197728B1 (en) * 1980-08-06 2001-03-06 Nissan Chemical Industries Ltd. Quinoxaline derivatives and herbicidal composition
US4760066A (en) * 1982-09-21 1988-07-26 Wayne State University Method for treating human tumor cell metastasis
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4710507A (en) * 1983-12-22 1987-12-01 Pfizer Inc. Quinolone inotropic agents
US5250690A (en) * 1985-05-02 1993-10-05 Dowelanco Haloalkoxy anilide derivatives of 2-4(-heterocyclic oxyphenoxy)alkanoic or alkenoic acids and their use as herbicides
JPS62190172A (ja) * 1986-02-14 1987-08-20 Teijin Ltd フエノキシ脂肪族カルボン酸誘導体および除草剤
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
AU5686794A (en) * 1992-12-15 1994-07-04 Du Pont Merck Pharmaceutical Company, The (2-quinoxalinyloxy)phenoxypropanoic acids and related derivatives as anticancer agents
WO1998008812A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Process for preparing pharmaceutical compounds
US6680311B1 (en) * 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
CA2264245A1 (en) * 1996-09-06 1998-03-12 Eli Lilly And Company Process to prepare pharmaceutical compounds
AU4821697A (en) * 1996-10-18 1998-05-15 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice
US6352991B1 (en) * 1997-01-08 2002-03-05 Wayne State University 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
US6238644B1 (en) * 1997-09-03 2001-05-29 Wayne State University Method for treating and/or imaging breast cancer using radioactive iodide
US6586461B1 (en) * 1998-06-16 2003-07-01 Wayne State University Prenyl transferase inhibitors
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
AU2001265182A1 (en) * 2000-05-30 2001-12-11 Rafael Fridman Inhibitors of matrix metalloproteinases
US6747021B2 (en) * 2000-10-02 2004-06-08 Eli Lilly And Company Cryptophycin compound
PL367340A1 (en) * 2001-07-31 2005-02-21 Wayne State University Quinoline derivatives and use thereof as antitumor agents
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents

Also Published As

Publication number Publication date
US7728007B2 (en) 2010-06-01
AU2003249722A1 (en) 2004-01-23
EP1539699A1 (en) 2005-06-15
GEP20074058B (en) 2007-03-12
WO2004004651A2 (en) 2004-01-15
US20040132618A1 (en) 2004-07-08
CA2491612C (en) 2012-01-03
US20060293333A1 (en) 2006-12-28
IL164555A0 (en) 2005-12-18
US7585863B2 (en) 2009-09-08
WO2004005260A1 (en) 2004-01-15
PL373624A1 (en) 2005-09-05
UA79293C2 (en) 2007-06-11
MXPA05000233A (es) 2005-04-11
SG145570A1 (en) 2008-09-29
US20090076073A1 (en) 2009-03-19
ZA200408191B (en) 2006-07-26
CA2491612A1 (en) 2004-01-15
AU2003249704A1 (en) 2004-01-23
JP2005532397A (ja) 2005-10-27
EA009679B1 (ru) 2008-02-28
AU2003249704B2 (en) 2010-05-20
NO20050573L (no) 2005-02-02
EA200500095A1 (ru) 2005-06-30
US7109341B2 (en) 2006-09-19
CN1688547A (zh) 2005-10-26
NZ535887A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0317524A (pt) Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
BR0108678A (pt) Novos compostos
BRPI0416656A (pt) compostos de pirrolopirimidina úteis no tratamento do cáncer
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
DK1664016T3 (da) Terapeutiske midler, der er anvendelige til behandling af smerter
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
DK1483251T3 (da) C3-cyano-epothilon-derivater
ATE238981T1 (de) Antitumorwirkstoffe
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
EP1453507A4 (en) SOLUBILIZED TOPOISOMERASE GIFT MEDIUM

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A E 8A ANUIDADES.